DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Intravenous Artesunate and Malaria

Information source: University of Khartoum
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Malaria

Intervention: artesunate (Drug); Quinine (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: University of Khartoum


Intravenous artesunate is egual to quinine in the treatment of severe malaria

Clinical Details

Official title: Intravenous Artesunate Versus Quinine in Severe Malaria at Kassla, Sudan

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: clearance of the parasite and fever

Detailed description: Intravenous artesunate is egual to quinine in the treatment of severe malaria in the form of fever clearance time and parasite clearance time


Minimum age: 1 Year. Maximum age: 80 Years. Gender(s): Both.


Inclusion Criteria: severe P. falciparum malaria- Exclusion Criteria:

mixed infection Pregnant women -

Locations and Contacts

Kassala, Kassala 249, Sudan; Recruiting
Abzinab A Ali, MD, Phone: +249911259199, Ext: 122, Email: ishagadamm@yahoo.com
Tajeldien A Abdulla, MD, Principal Investigator
Additional Information

Related publications:

Eltahir HG, Omer AA, Mohamed AA, Adam I. Comparison of artesunate and quinine in the treatment of Sudanese children with severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 2010 Oct;104(10):684-6. doi: 10.1016/j.trstmh.2010.05.009. Epub 2010 Jun 17.

Starting date: March 2013
Last updated: March 4, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017